Vital KSK Holdings, Inc. (TYO:3151)
Japan
· Delayed Price · Currency is JPY 1,259.00
+24.00 (1.94%)
May 30, 2025, 1:41 PM JST
Vital KSK Holdings Revenue
In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B JPY with 2.19% growth. Vital KSK Holdings had revenue of 139.69B in the quarter ending March 31, 2025, with 0.81% growth.
Revenue
600.37B
Revenue Growth
+2.19%
P/S Ratio
0.10
Revenue / Employee
162.04M
Employees
3,705
Market Cap
59.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,581.55B |
| HOYA Corporation | 869.37B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 997.33B |